CCCC
C4 Therapeutics, Inc.Company with tickers: CCCC
CIK
1662579
CUSIP
12529R107
Shares Outstanding
110,567,222
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $6,152,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $33,937,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $24,606,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-27,785,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-25,129,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.20 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.20 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |